The stated aims of the National Institute of Clinical Excellence are 'to improve standards of patient care, and to reduce inequities in access to innovative treatment'2. So much for the stated aims: NICE is about rationing3. Since the inception of state-organized healthcare, there has been a dialectical tension between the expectations of patients, the aspirations of healthcare professionals and the public purse. Explicitly, or more commonly implicitly, this has meant rationing. Politicians talk of setting priorities, but for rational decision-making one has to follow the advice of Marcus Aurelius: 'look things in the face and know them for what they are'4. RATIONING There is a danger in entering the debate on how to ration. It closes the question of whether sufficient resources are available without rationing. Healthcare professionals ought to lobby for more expenditure on behalf of their patients. When politicians talk of limited resources they are in reality talking of choices. They have chosen to spend on a new misile system or a new warship instead of a hospital. But let us suppose that rationing is inescapable. One method would be to limit expenditure on each individual, as food is rationed in time of war. However, most of us look at the provision of healthcare as a form of insurance. We hope we will never need it, but if we do we expect it to be available. We accept inequality in health resource utilization between individuals. It is one of the few aspects of public life where Marx's principal of 'to each according to his needs' holds. When we talk of rationing in terms of healthcare we usually mean limiting the availability of interventions. In 1988, The Lancet asked 'Which medical conditions shall we treat first?'5 and the question remains unanswered. Do we measure lives saved, gains in life expectancy or some artifice of quality of life and life gained6?
What about cost-effectiveness? The most cost-effective patient is a dead patient. Once one enters a costeffectiveness debate there is an inevitable slide into nihilism. There are serious flaws in the use of cost-effectiveness as a basis for rationing. Any cost saving is usually from a social budget and is not recoverable. Cost-effectiveness comparisons can inform debate but cannot direct it.
Some believe that 'evidence-based medicine' will help. The argument is that, if we restrict medical activity to interventions of proven benefit, then health costs will be dramatically reduced. But evidence-based medicine has been misused in rationing decisions7. There is confusion over what constitutes evidence. In its most extreme form, evidence-based medicine restricts consideration to the double-blind controlled trial, and many questions are not open to investigation by this technique8. If evidence-based medicine evaluates all available evidence, then it is doing no more than any respectable medical journal with its combination of review articles, opinion and primary research.
AIMS OF NICE
Any system of rationing has to be ethical, explicit, transparent, fair, flexible, consistent and capable of timely response to developments. How does NICE measure up? NICE has subdivided its aims into:
(i) Identify those new treatments likely to have a significant impact on the National Health Service (NHS) (ii) Enable evidence of clinical and cost effectiveness to be brought together (iii) Issue guidance on whether the treatment can be recommended (iv) Avoid significant delays to those sponsoring the innovation in either meeting any national or international regulatory requirements or bringing the innovation to market in the UK.
The last is curious since NICE will not be able, nor should it be able, to influence the European Agency for the Evaluation of Medicinal Products. Once a drug is licensed Keele University and North Staffordshire Royal Infirmary, Stoke-on-Trent ST4 7LN, UK E-mail: Simon@Northesk.demon.co.uk the drug can be prescribed in the UK. The only role NICE can have in this process is to stop or delay its use by the NHS. It is unlikely that pharmaceutical companies will substantially alter their development of new drugs for what is only 2.6% of the world market. There is a danger that the UK will become even more of a medical backwater.
The second aim is meaningless unless the cost-benefit ratio can be measured against something. This requires an overview of the whole of NHS spending. How much is the NHS willing to spend to save a life? Does it depend on how old you are, where you live, or whether you are a member of the government? NICE has not been set up in such a way as to solve this dialectic. Implicit in this aim is an overall capped budget within which there are competing therapies. It subverts arguments about the overall level of resourcing. It removes the blame for unavailability from politicians to the shoulders of those on the committee.
'It is envisaged that NICE will carry out annually 30-50 appraisals of the most significant new and existing interventions'9. In 1998, the Mutual Recognition Group of the European Agency for the Evaluation of Medicinal Products finalized procedures on 37 new active sub-stances10. NICE does not have sufficient capacity to deal with new chemical compounds coming to the market, never mind extensions of use or surgical procedures. So hospital and regional therapeutic committees will continue with their inadequate appraisals of new drugs and perpetuate the inequalities of access.
'NICE will work to a programme agreed with and funded from current resources by the Department of Health'9.
Like most government initiatives, NICE looks underresourced and over-ambitious. The result is likely to be substantial delays before treatments are considered-the antithesis to stated aim (iv).
EXPENSIVE NEW THERAPIES
The NHS Executive has urged health authorities to manage the entry of new therapies" I but two unfortunate tendencies have become apparent. The first is delay after delay; the second is adoption of a nihilistic mind-set. Surely this could not happen in 'a first class service'9. In 1993, fl-interferon was found efficacious in the treatment of relapsingremitting multiple sclerosis. Arnason A fundamental flaw of guidelines and evidence-based medicine is that they fail to cater for the individual. Let us imagine that NICE reviewed anti-epileptic drugs. There are four old and cheap anti-epileptic drugs and about five new more expensive ones. Phenobarbitone is the cheapest. It is also very efficacious. It causes drowsiness and some cognitive impairment, but the psychometric evidence on the other drugs is not very extensive. An honest costbenefit analysis would conclude that all patients with epilepsy should be on phenobarbitone. Not only would this put the treatment of epilepsy back 50 years but it would also fail to see patients as individuals. The 16-year-old sitting her GCSEs may be better on lamotrigine because of its good cognitive profile. The availability of more than nine anti-epileptic drugs is a good thing since it allows us to tailor our treatment to the individual. The logic of costbenefit analysis would be to recommend a single cheap and stupefying drug to all.
NOT SO NICE For a drug to be licensed it has to be demonstrated to be efficacious. NICE therefore has no role in determining efficacy. NICE will not speed up the introduction of drugs in the NHS; rather, it will provide another barrier. After looking at the stated aims of NICE I can only conclude that its true purpose is to deprive patients of treatment by delay.
